Literature DB >> 33643898

SH3KBP1 Promotes Glioblastoma Tumorigenesis by Activating EGFR Signaling.

Hai Song1, Yanpei Wang1, Chaojia Shi1, Jianxiang Lu1, Tian Yuan1, Xiangpeng Wang1.   

Abstract

Glioblastoma (GBM) is the most common and aggressive brain tumor in adults. Overexpression or activation of epidermal growth factor receptor (EGFR) occurs commonly in multiple human cancers and promotes tumorigenesis. However, the underlying molecular mechanism of EGFR aberrant activation and the downstream signaling pathways remains largely unknown. In this study, we report that both SH3-domain kinase binding protein 1 (SH3KBP1) mRNA and protein levels are highly expressed in GBM and its high expression is associated with worse survival of glioma patients. In addition, we provide evidence that SH3KBP1 is prominently expressed in GBM stem cells (GSCs) and have potential to serve as a novel GSCs marker. Moreover, silencing SH3KBP1 dramatically impairs GBM cell proliferation, migration and GSCs self-renewal ability in vitro and xenograft tumors growth in vivo. Most importantly, we found that SH3KBP1 directly interacts with EGFR and may act as an adaptor protein to transduce EGFR signaling. Together, our work uncovers SH3KBP1 as a novel regulator of oncogenic EGFR signaling and also as a potential therapeutic target for GBM patients with EGFR activation.
Copyright © 2021 Song, Wang, Shi, Lu, Yuan and Wang.

Entities:  

Keywords:  SH3KBP1; adaptor; epidermal growth factor receptor; glioblastoma; glioblastoma stem cells

Year:  2021        PMID: 33643898      PMCID: PMC7905166          DOI: 10.3389/fonc.2020.583984

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  39 in total

1.  Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.

Authors:  Agda K Lucio-Eterovic; Yuji Piao; John F de Groot
Journal:  Clin Cancer Res       Date:  2009-06-30       Impact factor: 12.531

2.  SH3GL3 functions as a potent tumor suppressor in lung cancer in a SH3 domain dependent manner.

Authors:  Zhongkun Lin; Zhiping Liu; Xiansheng Tan; Chunhua Li
Journal:  Biochem Biophys Res Commun       Date:  2020-11-07       Impact factor: 3.575

Review 3.  EGFR and cancer prognosis.

Authors:  R I Nicholson; J M Gee; M E Harper
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

Review 4.  Glioblastoma multiforme: Pathogenesis and treatment.

Authors:  Constantinos Alifieris; Dimitrios T Trafalis
Journal:  Pharmacol Ther       Date:  2015-05-02       Impact factor: 12.310

5.  TRIM59 Promotes Gliomagenesis by Inhibiting TC45 Dephosphorylation of STAT3.

Authors:  Youzhou Sang; Yanxin Li; Lina Song; Angel A Alvarez; Weiwei Zhang; Deguan Lv; Jianming Tang; Feng Liu; Zhijie Chang; Shigetsugu Hatakeyama; Bo Hu; Shi-Yuan Cheng; Haizhong Feng
Journal:  Cancer Res       Date:  2018-01-31       Impact factor: 12.701

6.  EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.

Authors:  Qi-Wen Fan; Christine K Cheng; W Clay Gustafson; Elizabeth Charron; Petra Zipper; Robyn A Wong; Justin Chen; Jasmine Lau; Christiane Knobbe-Thomsen; Michael Weller; Natalia Jura; Guido Reifenberger; Kevan M Shokat; William A Weiss
Journal:  Cancer Cell       Date:  2013-10-14       Impact factor: 31.743

7.  Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.

Authors:  Jeffrey C Lee; Igor Vivanco; Rameen Beroukhim; Julie H Y Huang; Whei L Feng; Ralph M DeBiasi; Koji Yoshimoto; Jennifer C King; Phioanh Nghiemphu; Yuki Yuza; Qing Xu; Heidi Greulich; Roman K Thomas; J Guillermo Paez; Timothy C Peck; David J Linhart; Karen A Glatt; Gad Getz; Robert Onofrio; Liuda Ziaugra; Ross L Levine; Stacey Gabriel; Tomohiro Kawaguchi; Keith O'Neill; Haumith Khan; Linda M Liau; Stanley F Nelson; P Nagesh Rao; Paul Mischel; Russell O Pieper; Tim Cloughesy; Daniel J Leahy; William R Sellers; Charles L Sawyers; Matthew Meyerson; Ingo K Mellinghoff
Journal:  PLoS Med       Date:  2006-12       Impact factor: 11.069

8.  Inhibition of CIN85-mediated invasion by a novel SH3 domain binding motif in the lysyl oxidase propeptide.

Authors:  Seiichi Sato; Yingshe Zhao; Misa Imai; Philip C Simister; Stephan M Feller; Philip C Trackman; Kathrin H Kirsch; Gail E Sonenshein
Journal:  PLoS One       Date:  2013-10-22       Impact factor: 3.240

Review 9.  Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.

Authors:  Zhenyi An; Ozlem Aksoy; Tina Zheng; Qi-Wen Fan; William A Weiss
Journal:  Oncogene       Date:  2018-01-11       Impact factor: 9.867

10.  Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results.

Authors:  Takahiro Oike; Yoshiyuki Suzuki; Ken-ichi Sugawara; Katsuyuki Shirai; Shin-ei Noda; Tomoaki Tamaki; Masaya Nagaishi; Hideaki Yokoo; Yoichi Nakazato; Takashi Nakano
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

View more
  3 in total

Review 1.  Glioblastoma Stem Cells-Useful Tools in the Battle against Cancer.

Authors:  Silvia Mara Baez Rodriguez; Georgiana-Adeline Staicu; Ani-Simona Sevastre; Carina Baloi; Vasile Ciubotaru; Anica Dricu; Ligia Gabriela Tataranu
Journal:  Int J Mol Sci       Date:  2022-04-21       Impact factor: 6.208

2.  Development and Validation of a Liquid-Liquid Phase Separation-Related Gene Signature as Prognostic Biomarker for Low-Grade Gliomas.

Authors:  Lidong Ning; Guanyan Zhao; Changji Xie; Huan Lan; Jiefei Chen; Hu Tan; ChengCong Wei; Zhiyu Zhou
Journal:  Dis Markers       Date:  2022-09-23       Impact factor: 3.464

Review 3.  Targeting Glioblastoma Stem Cells: A Review on Biomarkers, Signal Pathways and Targeted Therapy.

Authors:  Xuejia Tang; Chenghai Zuo; Pengchao Fang; Guojing Liu; Yongyi Qiu; Yi Huang; Rongrui Tang
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.